HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial (Q51751068)

11 April 2018

title

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial (English)

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

multicenter clinical trial

17 July 2024

main subject

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

5

Andreas Schneeweiss

1 reference

11 April 2018

3

Bahriye Aktas

1 reference

11 April 2018

author name string

Tanja Fehm

1

1 reference

11 April 2018

Volkmar Müller

2

1 reference

11 April 2018

Wolfgang Janni

4

1 reference

11 April 2018

Elmar Stickeler

6

1 reference

11 April 2018

Claus Lattrich

7

1 reference

11 April 2018

Erich Solomayer

9

1 reference

11 April 2018

Brigitte Rack

10

1 reference

11 April 2018

Sabine Riethdorf

11

1 reference

11 April 2018

Christoph Klein

12

1 reference

11 April 2018

Christian Schindlbeck

13

1 reference

11 April 2018

Kerstin Brocker

14

1 reference

11 April 2018

Sabine Kasimir-Bauer

15

1 reference

11 April 2018

Diethelm Wallwiener

16

1 reference

11 April 2018

Klaus Pantel

17

1 reference

11 April 2018

Christian R. Löhberg

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20859679

17 July 2024

language of work or name

English

0 references

publication date

22 September 2010

1 reference

11 April 2018

full work available at URL

https://hal.archives-ouvertes.fr/hal-00578726/file/PEER_stage2_10.1007%2Fs10549-010-1163-x.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20859679

http://link.springer.com/content/pdf/10.1007/s10549-010-1163-x.pdf

17 July 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

http://link.springer.com/article/10.1007/s10549-010-1163-x/fulltext.html

17 July 2024

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

http://link.springer.com/content/pdf/10.1007/s10549-010-1163-x

17 July 2024

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Breast Cancer Research and Treatment

17 July 2024

published in

1 reference

11 April 2018

volume

124

1 reference

11 April 2018

issue

2

1 reference

11 April 2018

page(s)

403-412

1 reference

11 April 2018

Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells.

cites work

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/312513A0

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

17 July 2024

3

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

17 July 2024

4

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.

17 July 2024

5

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

17 July 2024

6

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me

17 July 2024

7

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

17 July 2024

8

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

17 July 2024

9

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?

17 July 2024

10

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

17 July 2024

11

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

17 July 2024

12

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Change of HER-2/neu status in a subset of distant metastases from breast carcinomas

17 July 2024

13

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review

17 July 2024

15

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.

17 July 2024

16

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

17 July 2024

18

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

17 July 2024

19

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.

17 July 2024

20

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

17 July 2024

21

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.

17 July 2024

22

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells

17 July 2024

23

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients

17 July 2024

24

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial

17 July 2024

25

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

HER-2 gene amplification can be acquired as breast cancer progresses

17 July 2024

28

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK

17 July 2024

29

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Reporting recommendations for tumor marker prognostic studies (REMARK).

17 July 2024

30

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer

17 July 2024

33

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival

17 July 2024

34

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

17 July 2024

35

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

17 July 2024

36

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies

17 July 2024

37

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1163-X

17 July 2024

Identifiers

1 reference

11 April 2018

1 reference

11 April 2018